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B.P. Mwipatayi,1* S.J. Beningfield,3 L.E. White,2 A. Irish,2 M. Abbas1 and
K. Sieunarine11Department of Vascular Surgery, 2Renal Unit, Royal Perth Hospital, Perth, WA, Australia; and 3Division of
Radiology, Groote Schuur Hospital, Cape Town, South AfricaPurpose. Atherosclerotic renal artery stenosis (ARAS) is associated with morbidity and mortality consequent to progressive
ischemic renal failure and the cardiovascular consequences of hypertension. There is considerable uncertainty concerning the
optimal management of patients with this condition. This review considers the aetiological factors and the physiologic
consequences of ARAS and compares the results of clinical studies of medical and endovascular therapies on blood pressure
control and preservation of renal function.
Results. Although, in patients with fibromuscular disease the results of percutaneous transluminal angioplasty (PTA) are
clearly superior to medical therapy and surgery, in asymptomatic patients with ARAS the antihypertensive benefits and
preservation of renal function of endovascular, surgical and medical therapies appear similar. In selected symptomatic
patients interventions may, however, be life-saving. Surgery is generally reserved for arterial occlusions with preserved renal
parenchyma and function.
Conclusions. The results of larger, multicentre, randomised, controlled trials are required to clearly clarify the role of
interventional therapy in asymptomatic patients.Keywords: Renal artery stenosis; Percutaneous transluminal angioplasty; Stenting; Antihypertensive therapy.Introduction
A stenosis of the renal artery that reduces blood flow
to the kidney, sufficiently to reduce normal perfusion
and glomerular filtration, activates protective systems
aimed at preserving renal blood flow. Activation of the
renin-angiotensin system can cause hypertension as a
result of peripheral vasoconstriction and sodium
retention through the contralateral kidney. Progressive
luminal narrowing can lead to renal ischemia, which
initiates a process of intra-renal structural and func-
tional change with progressive loss of renal mass and
function. When bilateral this may cause renal failure.
Atherosclerotic renal artery stenosis (ARAS) is the
most common cause of renal artery stenosis. Under-
standing the natural history of ARAS is important to
enable appropriate decisions concerning theing author. B.P. Mwipatayi, FCS (SA), MMed (Surg),
of Vascular Surgery, Royal Perth Hospital, Wellington
WA 6000, Australia.
: bibombe@iinet.net.au
0479+ 10 $35.00/0 q 2005 Elsevier Ltd. All rights reserindications, type and timing of renal artery interven-
tions to be made.1
Careful differentiation between the following three
terms needs to be borne in mind: Renal artery stenosis
(RAS), renovascular hypertension and ischemic
nephropathy. RAS refers to the anatomic (or radio-
graphic) narrowing of the renal artery lumen, but does
not imply the presence of physiologic consequence. In
contrast, both renovascular hypertension and ischemic
nephropathy are clinico-pathologic entities. Renovas-
cular hypertension is hypertension that is the direct
consequence of renal artery stenosis. Physiologically,
this hypertension may be secondary to increased
activation of the renin-angiotensin system (dominant
in unilateral renal artery disease), or due to volume
overload (a major factor in bilateral disease or in the
patient with a solitary kidney), or due to a combination
of both.2,3 This diagnosis can sometimes only be made
in retrospect, when correction of the stenosis improves
the hypertension.
Ischemic nephropathy refers to a progressive loss ofEur J Vasc Endovasc Surg 29, 479–488 (2005)
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features of focal glomerular sclerosis with ischemic
tuft retraction, peri-glomerular fibrosis, and tubulo-
interstitial fibrosis. Functionally, there is a progressive
decrease in glomerular filtration rate with proteinuria,
hypertension and sodium retention as the clinical
features. In severe cases, uraemia due to end-stage
renal failure may occur.2
In general, interventions for RAS are considered to
cure or ameliorate hypertension, to prevent or reverse
progressive renal dysfunction or, in rare cases, for the
symptomatic relief of severe fluid overload (as
manifested by pulmonary oedema), often in the
setting of a single functioning kidney or bilateral
RAS. Historically, surgical reconstruction of the renal
artery has been the standard treatment for ARAS, but
recently medical and endovascular options have
become more established.4 The surgical techniques
include aortorenal endarterectomy and aortorenal,
hepatorenal or splenorenal bypass and autotransplan-
tation.5 Surgery still retains a role in complex
reconstructions for medically suitable patients when
correcting a renal artery occlusion can restore renal
function and avoid dialysis. Surgery is also often
indicated in patient with RAS requiring aortic surgery
for other reasons. This paper, however, concentrates
on the current evidence of the benefits and risks of
therapeutic interventions with medical therapy com-
pared to endovascular procedures for renal artery
stenoses.Methods and Results
A comprehensive search for key articles using the
Ovid, Medline, Embase and Journals Fulltext@Ovid
from 1952 to March 2004 was performed, using the
following combinations of key phrases: ‘clinical’ or
‘controlled randomised trial’, ‘review articles’, ‘natural
history’, ‘renal artery stenosis’, ‘medical treatment’,
‘surgery’, ‘endovascular”, ‘percutaneous transluminal
angioplasty’ and ‘stenting’. The Cochrane Collabor-
ation database from 1970 to March 2004 was also
searched for the same information. The publications
obtained (5703) were then further searched for clinical
trials. This yielded a total of 151 publications. Only
randomised trials (28) and meta-analysis (7) were
considered for analysis. The abstracts were then read
to see if those randomised trials had sufficient number
of patients to be able to reach a substantial conclusion
(studies with sample size calculated on the basis of a
significance level of 5% and on a power of 80%). When
this was not clear from the abstract, the full paper was
obtained. All co-authors involved in the developmentEur J Vasc Endovasc Surg Vol 29, May 2005of this paper added relevant papers according to their
specialties if they were not included in the initial
search: surgery (KS), nephrology (AI) and radiology
(SB).Asymptomatic atherosclerotic renal artery stenosis (ARAS)
The prevalence of renovascular disease in the general
population is difficult to ascertain as there are no easily
applicable screening tests. In post-mortem studies,
‘silent’ ARAS is noted in up to 6% of the population.6
In selected populations undergoing angiography for
atherosclerosis in other vascular beds, the prevalence
of ARAS was noted to be between 28% (where the
primary investigation was coronary angiography) and
50% (for peripheral arterial angiography).7,8
Additional risk factors for ARAS are poorly under-
stood, but smoking, age and diabetes have been
correlated in epidemiological studies.8 The most likely
reason for death in patients with ARAS is a cardiac
cause. Patients with ARAS also have a significantly
reduced survival, consistent with the diffuse nature of
their atherosclerosis burden. This reduced survival is
important when considering studies of the natural
progression of ARAS and the risk and benefits of
interventions. Alejandro et al. have developed a swine
model of ARAS which suggests that injury to the
endothelium in an atherosclerotic milieu of hyperlipi-
demia and hypertension is required for the develop-
ment of ARAS.9
Natural history studies for ARAS require serial
follow-up of large numbers of patients, as with other
vascular diseases. Previously, contrast angiography
was the only method available for evaluating renal
artery disease; early reports of the natural history of
RAS, therefore, included only patients undergoing
sequential arteriogram. The use of duplex scanning
now permits non-invasive evaluation of renal arteries,
although less reliably than with angiography
(Table 1).10–15
Two prospective follow-up studies of ARAS with-
out intervention based on serial duplex scanning have
been reported by Zierler et al.14,15 The first, provided
data on 80 patients with 139 renal arteries who were
followed for a mean period of 12.7 months. The
occlusion rate was 5% at 12 months and 11% at 24
months. No association between the multiple risk
factors analyzed and progression of renal artery
disease was found.
A follow-up study of a different group of patients
was also analyzed, and included 132 renal arteries.15
There were four renal arteries that progressed to
occlusion; all of these had at least 60% stenosis initially.
Table 1. Outcome of asymptomatic renal artery stenosis
Authors No. of patients Investigations Follow-up* Outcome
Wollenweber11 30 Arteriography 42 months Progression in 50%
Meaney12 39 Arteriography Up to 10 years Progression in 50%
Schreiber13 85 Arteriography 52 months Progression in 44%
Occlusion in 16%
Tollefson14 48 (RA) Arteriography 7.3 years (mean) Progression in 53%
Occlusion in 9%
Zierler15 80 (139 RA) Duplex scan 24 months Under 60% to over 60%
stenosis in 42%
Occlusion in 11%
Zierler16 132 RA Duplex scan 3 years Progression in 7% per
year on average
RA, renal arteries; RAO, renal artery occlusion; RAS, renal artery stenosis.
* Follow-up period.
Renal Artery Stenosis 481Progression of RAS occurred at an average rate of 7%
per year for all categories but stenosis of R60%,
progression is 30% at 1-year and 48% at 3-years follow-
up. The progression of ARAS, therefore, appears to be
relatively slow and no factor, other than the initial
degree of stenosis, could predict those at risk of
occlusion. Because both studies included only patients
with hypertension and/or renal failure who were
unsuitable for renal revascularisation at the time of
their baseline evaluations, the generalisation of these
findings to other patient groups is probably limited.Symptomatic renal artery stenosis
The consequences of high grade RAS can be dramatic
and severe. These include accelerated or malignant
hypertension with papilloedema, acute to chronic
renal impairment and acute left ventricular failure
and hypertrophy. Typically, this is seen in unilateral
disease where the contralateral kidney is unimpaired.
Intervention, before occlusion or atrophy of the
affected kidney occurs, can reverse these acute
changes. Both percutaneous transluminal angioplasty
(PTA) and surgery have been recommended in these
cases.
A syndrome of acute pulmonary edema with or
without renal failure has been described in patients
with either high-grade stenosis of a single kidney or
with bilateral disease, often with one renal artery
occluded and the other stenosed.16,17 Sometimes these
cases are unmasked by the use of renin-angiotensin
inhibitors. Typically, these patients present with severe
and rapid onset pulmonary edema, often with
associated renal dysfunction, and the term ‘flash
pulmonary edema’ have been coined for this entity.
The syndrome may be confused with coronary
syndromes (which may also be present) and the
diagnosis can require a high degree of clinical
alertness.18 Determinants of successful outcomeusually include evidence of preserved renal parench-
yma or renal reserve, and may require renal biopsy
and nuclear scanning to demonstrate viability and
probability of response to intervention. Intervention
with either PTA or surgery may resolve these
symptoms and allow stabilisation of renal dysfunc-
tion. However, these publications are largely case
reports and not subject to statistical analysis.ARAS with hypertension and/or chronic renal dysfunction
The majority of patients with ARAS are identified
during the investigation of hypertension or chronic
renal impairment. RAS most commonly occurs as a
result of atherosclerosis (90%), and is far less fre-
quently due to fibromuscular dysplasia or other
conditions. Fibromuscular dysplasia rarely results in
renal failure.19 PTA is usually curative, whereas the
optimal treatment for atherosclerotic renovascular
disease is uncertain.20
The pathophysiology of hypertension occurring in
association with ARAS is complex. According to
Haller, most patients have essential hypertension
complicated by the renovascular disease.20 Hyperten-
sion in renovascular disease can be due to increased
activation of the renin-angiotensin system, or may be
the result of volume overload. Often both are thought
to be contributory, particularly as underlying par-
enchymal kidney damage may co-exist. The long-term
end-organ damage of chronic hypertension leads to
left ventricular hypertrophy, nephrosclerosis, small
vessel cerebral ischemia (as seen by lacunar infracts),
and contributes further to the progression of ARAS in
a vicious cycle of injury.21
Ischemic nephropathy in RAS may occur as a result
of the lowered blood pressure and flow beyond the
stenosis.19 This can lead to impaired renal function,
and ultimately, end-stage renal disease requiring
dialysis or transplant with the associated skeletal,Eur J Vasc Endovasc Surg Vol 29, May 2005
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and hematologic co-morbidities.21 Concurrently; the
opposite kidney may also be damaged by exposure to
hypertension. Paradoxically, the stenosed artery can
protect the ipsilateral kidney by reducing intra-
glomerular pressure.
There is a large body of observational evidence
indicating that progression of renovascular disease
precedes renal failure.20,22 A recent prospective anal-
ysis found that renovascular disease accounted for 5–
15% of all patients progressing to dialysis each year.23
Mortality rates of those with end-stage renal failure
due to RAS were high, with more than 50% of the
cohort dying over the 3-years of the study.23 The
authors concluded that RAS is underreported due to
the difficulties in establishing a diagnosis, although the
detection of this disease had risen steadily over time in
their centre. The use of various risk factors has been
proposed to identify those patients likely to benefit
from the correction of renal-artery stenosis. Raderma-
cher et al. found that a renal artery duplex Doppler
resistance index value of at least 0.8 before revascular-
isation was a strong predictor of worsening renal
function and a lack of improvement in blood pressure,
despite the correction of renal artery stenosis.24
Conversely, lower resistance indices were associated
with an improvement in both renal function and blood
pressure after the correction of renal-artery stenosis.
This may indicate that fixed parenchymal injury due
to longstanding hypertension or other processes such
as diabetes, nephrosclerosis, ischemic fibrosis and
focal glomerulosclerosis, is not reversible with
upstream interventions, irrespective of how significant
or otherwise the stenosis may be. Proposed clinical
indicators of poor response include renal size (!8 cm),
degree of proteinuria (possibly reflecting glomerular
injury) and degree of renal impairment (the more
advanced, the lower the chance of success).24InterventionsSurgical revascularisation
Surgical revascularisation plays a much smaller role
than it had previously, due to the excellent technical
results achievable with angioplasty and stenting.
There have been few publications comparing surgery
and medical or endovascular therapies, with only two
randomised papers available. Weilbull et al. in 1993
published the result of their prospective randomised
study on 58 patients. They compared renal artery
angioplasty and operation as initial therapy with
regard to technical results, primary and secondary
patency, and effects on blood pressure and renalEur J Vasc Endovasc Surg Vol 29, May 2005function in patients with atherosclerotic unilateral
renal artery stenosis. The technical success rate was
83% in the angioplasty group and 97% in the surgical
group (pZ0.19). The primary patency was statistically
significant (pZ0.05) by an efficacy test (75% in the
angioplasty group and 96% in the surgical group) but
the secondary patency was similar for both treatment
options (pZ0.61). The effect on blood pressure: the
primary and secondary results in both group was not
statistically significant (pZ0.52 for primary, pZ1 for
secondary results). The corresponding figures for
improved or unchanged renal function were 83 and
72%, respectively, which was a non-significant differ-
ence (pZ0.53). The authors concluded that translum-
inal angioplasty is recommendable as initial therapy
for unilateral atherosclerotic renal artery stenosis
causing renovascular hypertension if combined with
intensive follow-up and aggressive reintervention.
This study does have numerous limitations. The
inclusion criteria are strict and are not representative
of patients with atherosclerotic renal artery stenosis.
They specifically state that only unilateral disease was
admissible for the study. Secondly, the patients were 70
years old or younger and non-diabetic. However,
treatment of critical renal artery stenosis in older
atherosclerotic populations is common and poses a
therapeutic challenge. It would seem appropriate that
the authors should have limited their conclusions to
this study group only. Thirdly, the follow-up period
and the numbers in the study is limited.25
A second randomised study compared ‘Medical
versus Surgical management of atherosclerotic renal
artery stenosis’. The goal of the study was to compare
differences in event-free survival between patients
with RAS managed by either therapeutic modality. A
total of 67% of patients reached an end point, namely
67% in the medical group and 68% in the surgical
group. There were no statistically significant differ-
ences in the end points reached between the groups.
The median time to reach an end point was similar in
both groups (medical 62 months, surgical 69 months:
pZ0.75). There were no statistically significant differ-
ences in survival (pZ0.31), dialysis-free survival (pZ
0.64), or and blood pressure control (pZ0.2). The
overall median follow-up was 74 months. Analysis of
variance comparing changes in GFR over time
between the groups also yielded no statistically
significant differences. Although, the data suggests
minimal differences between these groups, the power
of the study is limited by the relatively small sample
size (nZ52). Therefore, the statistical power to detect
even rather large differences between the groups, such
as a twofold change in the median survival, was only
53%. This study is also hampered by the negative
Renal Artery Stenosis 483impact of follow-up angiography in patients with
already deteriorating renal function.26
Current indications for surgical revascularisation
include: occluded renal artery with preserved renal
parenchyma, RAS with Takayasu’s arteritis, branch
disease from FMD that cannot be treated adequately
with balloon angioplasty;27 recurrent stenosis after
stenting28 or simultaneous aortic surgery (abdominal
aortic aneurysm repair or symptomatic aortoiliac
disease). Even in this last circumstance, it may be
advisable to stent the renal artery first and then
proceed with aortic reconstruction. The mortality rate
of aortic replacement and renal artery revascularisa-
tion is higher than for either procedure alone.29
Medical therapy
Angiotensin-converting enzyme inhibitors (ACEi) are
frequently prescribed for hypertension due to their
effectiveness in blocking this renal compensatory
mechanism and lowering blood pressure, thereby
protecting the kidney’s function in the longer term.
ACEi drugs are often the treatment of choice for
patients with chronic renal dysfunction as they
preferentially reduce intra-glomerular pressure by
reducing efferent arteriolar resistance.20 Calcium-
channel blockers, which maintain renal perfusion by
their preferential effect on reducing afferent arteriolar
tone, and beta-blockers (which lower renin), are also
established options for patients with renovascular
disease. However, there is little research specifically
comparing the efficacy of these antihypertensive
agents in renovascular hypertension. Haller’s sugges-
tion that most patients with renal artery stenosis
probably have essential hypertension rather than
renovascular hypertension, means that treating the
renovascular disease is unlikely to cure hypertension
in these patients.20 Chabova et al. reported their
experience in treating 231 hypertensive patients with
more than 70% RAS with ACE inhibitors, calcium-
channel blockers and diuretics. The mortality over 5
years in this group was 28%. The risk of progressiveTable 2. Randomised controlled trials of PTA versus sole medical th
Study Patients Intention
to treat
Renal function
EMMA27
(Plouin 1993)
26 medical; 23
angioplasty
No At 6 months: no clear
difference in creatinin
(pZ0.73)
SNRASCG28
(Webster 1998)
30 medical; 25
angioplasty
No No clear difference in
creatinine
DRASTIC29
(Van Jaarsveld
2000)
50 medical; 56
angioplasty
Yes At 3 months: differen
outcome (pZ0.03); at
months: no clear diffe
in creatinine (pZ0.11renal failure was 19% in patients with bilateral renal
artery stenosis and 12.8% with unilateral disease over
5 years. Revascularisation was required in 8.8% for
progressive or non-responsive hypertension and/or
renal dysfunction.30 Caution is recommended with
ACE inhibitors, especially in bilateral RAS because
renal function can be compromised due to their
dilatory effect on the efferent arterioles. This can
reduce the capillary pressure within the glomerulus
to below the critical perfusion pressure31 and cases of
acute renal failure can occur under these
circumstances.20
Medical versus endovascular therapy
Three randomised controlled trials [the Essai Multi-
centrique Medicaments versus Angioplastie (EMMA)
trial,32 the Scottish and Newcastle Renal Artery
Stenosis Collaborative Group (SNRASCOG) trial33
and the Dutch Renal Artery Stenosis Intervention
Cooperative Group (DRASTIC) trial34] compare PTA
with medical treatment in renovascular hypertensive
patients (Table 2). These studies were the focus of a
Cochrane review undertaken in 2003.35 The primary
outcomewas blood pressure. This composite review of
210 patients with moderate to severe RAS recorded no
statistically significant difference between PTA and
medical therapy in reducing systolic blood pressure,
although there was a difference in mean arterial
pressure of K7 mmHg in favour of PTA, (CI K12 to
K1 mmHg). There was no difference in renal function
outcome, despite the finding that PTA resulted in
improved patency of renal arteries after 12 months
(odds ratio (OR) 4.2 (CI: 1.8–9.8)). PTA also reduced
the number of antihypertensives drugs required and
there were fewer complications of these agents (ORZ
0.27, pZ0.09). The review, therefore, concluded that
there was some modest benefit of PTA for reducing
blood pressure in these patient.35 The finding that
there was no difference in renal function is supported
by others,36,37 which demonstrates that single kidney
glomerular filtration rate (GFR) and the degree of renalerapy
Blood pressure Patients with-
drawn or lost
to follow-up
Crossover from
medical therapy
to angioplasty
(%)
e
No BP difference
(pZ0.90)
1 7(27)
No BP difference 6 0
ce in
12
rence
)
At 12 months: no
difference in BP
(pZ0.51)
2 22(44)
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after PTA, implying that the outcome is determined
not by narrowing of the large renal arteries, but rather
by the reversibility of intra-renal small vessel disease.
The three trials discussed all have limitations; pre-
dominantly the risk of type one errors due to small
sample sizes (Table 3). Since, there were only a few
cardiovascular and renovascular complications in all
three of the Cochrane review trials, these are grouped
together in Fig. 1. Major cardiovascular and renovas-
cular complications occurred in 10 of 104 patients
undergoing PTA (9.6%), compared to 26 of 106 patients
(24.5%) treated medically [OR 0.32 (95% CI 0.15–0.70)].
Both individual cardiovascular [OR 0.41 (95% CI 0.16–
1.07)] and renovascular complications [OR 0.32 (95%
CI 0.10–0.97)] were less frequent in PTA than in
medically treated patients.
According to Haller, the main reason for perform-
ing revascularisation with PTA and/or stenting is to
improve and preserve renal function.20 There is,
however, no conclusive evidence that renal revascu-
larisation slows the deterioration of renal function.
There are no randomised controlled trials that focus on
renal failure as the sole outcome measure, either for
PTA or stenting.The evidence for stenting
As seen from the trials quoted above, there appears to
be no conclusive difference in renal function outcome
between PTA and medical therapy. One of the trials
previously mentioned34 does not distinguish between
stenting and PTA, but includes the results from two
patients with stents alongside those who underwent
PTA alone. There is a single published randomised
controlled trial comparing stenting to PTA alone in
RAS, although many cohort studies have been
performed. Van de Ven et al performed a randomised
controlled trial in 1999 comparing 42 patients under-
going PTA for RAS with 45 undergoing PTA and
stenting.38 The outcome assessors were blinded, the
procedures used were carefully described and the data
were analysed on an intention-to-treat basis. TheTable 3. Complication of PTA (Gstenting) of renal arteries33,34,44–46
Local renal (3–83%)
1. Contrast-induced ARF (mild or severe)
2. Atheroembolic renal failure (0.5%)
3. Rupture of the renal artery
4. Dissection of the renal artery
5. Thrombotic occlusion of the renal artery (2%)
6. Occlusion of a branch renal artery (0.5%)
7. Balloon rupture or malfunction (may lead to inability to remove
balloon)
8. Renal artery spasm
The exact risk of complications is difficult to quantify because of differ
Eur J Vasc Endovasc Surg Vol 29, May 2005success rate and patency rate with stenting were
found to be significantly higher for stenting than with
PTA alone with a 31% difference, but a wide
confidence interval of 12–50%. Renal function and
blood pressure in both groups was stable or
unchanged at 6-month follow-up, with no significant
difference between the PTA and stent groups. Cure or
improvement of hypertension was 9% better in the
stenting group, but this was not statistically signifi-
cant, again with a wide confidence interval of K31–
13%.
In a retrospective cohort, evaluated by Rundback et
al.,39 a group of 69 patients were compared over a 42-
month period. Forty underwent PTA and stent
placement, while 15 had PTA in isolation. The overall
benefit as determined by function, patency and long-
term success in the PTA group was 40% and in the
stenting group 66%, which was a significant difference
(p!0.05).
Other cohort studies examining the outcome of
stenting with sample sizes ranging from 100 to 200
patients have reported stabilisation of renal function
and improvement in blood pressure.40–44 These largely
retrospective studies all had follow-up times of
between 3 and 5 years, and employed simple
prevalence data analyses without providing p values
or confidence intervals.41–44 Similar findings were
demonstrated in smaller scale cohort studies focusing
on renal function alone, specifically improvement of
previously declining renal function and overall stabil-
ised creatinine levels.31,42,45,46 While many of these
studies have sampling and analytical limitations, they
all demonstrate similar trends in outcomes.42,45–47
There is a need for further randomised clinical trials
in the area of stent deployment to clarify and possibly
confirm the benefits suggested by the cohort studies.
Several trials specifically examining the renal outcome
of PTA versus stenting are currently underway. The
Ischemic Nephropathy Study Group of the Italian
Society of Nephrology has organized the 3 R Study
(renal outcome in renal ischemia: revascularisation or
medical treatment), a prospective, controlled studyPuncture site
1. Haematoma, haemorrhage or vessel tear (3–48%)
2. Brachial plexus compression (axillary approach)
3. Pseudoaneurysm (0.5%)
4. AV fistula (0.1%)
ing reporting standards.
Fig. 1. Cardiovascular and renovascular complications in patients treated with PTA and medical therapy in EMMA,
SNRASCG and DRASTIC trials.
Renal Artery Stenosis 485over a period of 3 years, aimed at comparing the effect
of endovascular revascularisation versus medical
therapy in 300 patients with RAS who will be
randomly assigned to the two treatment arms.48
Patients with angiographic ARAS of between 50 and
90% and creatinine levels of less than 4 mg/dl
(352 mmol/l) will be included. End points will be
cardiovascular mortality and morbidity, and the need
for renal replacement therapy.
The STAR-study49 (benefit of STent placement and
blood pressure and lipid-lowering for the prevention
of progression of renal dysfunction caused by Athero-
sclerotic ostial of the Renal artery) aims to compare the
effects of renal artery stenting together with medi-
cation, versus medication alone on renal function in
ARAS. Patients with RAS of greater or equal to 50%
and renal failure (creatinine clearance !80 ml/min/
1.73 m2) will be randomly assigned to stent placement
with medication or to medication alone. Medication
consists of statins, antihypertensive drugs and anti-
platelet therapy. Patients are to be followed for a
minimum of 2 years, with extended follow-up to 5
years. The primary outcome of this study is a
reduction in creatine clearance of over 20% compared
to baseline. The intention is to recruit 140 patients.
Similarly, the ASTRAL (PTA and stenting for renal
artery lesions) trial aims to randomise up to 1000patients between endovascular revascularisation with
medical treatment, versus medical treatment alone.
Any patient with ARAS and at least one ARAS lesion
that is suitable for PTA and/or stenting confirmed by
angiography, with no prior revascularisation pro-
cedure for ARAS and no definite contraindication to
revascularisation is included.Complications of PTA
In general, these have been divided into those
involving the puncture site (such as hematoma,
pseudoaneurysm or arteriovenous fistula formation),
the renal artery (including dissection, thrombosis,
rupture, atheroembolism, perinephric bleeding or
worsening renal function), contrast medium nephro-
toxicity and systemic (myocardial infarction or stroke)
(Table 3).38,39,50–52
Yutan reported overall 30-day morbidity (5%) and
mortality (4%) rates in a group of patients undergoing
PTA.53 These complications may equally be observed
with stenting. Puncture site complications are gener-
ally minor, although the presence of hypertension,
procedural heparinisation and larger sheaths do
predispose to problems. When the axillary artery
approach is used (usually because of severe aortoiliac
occlusive atherosclerosis), brachial plexus damage is aEur J Vasc Endovasc Surg Vol 29, May 2005
B. P. Mwipatayi et al.486risk if haematoma formation occurs. The brachial
approach is preferred by many.
Acute renal failure (ARF), defined as a transient rise
in serum creatinine to more than 25% above the
baseline, may be due to contrast medium toxicity,
atheroemboli or intrarenal vasoconstriction.50,54 Dis-
section of the renal artery or occlusion of the main or
branch renal arteries occasionally occurs. Direct
toxicity of iodinated contrast medium to nephrons
appears to be related to the osmolality of the contrast.
Intrarenal vasoconstriction is a vascular response to
contrast media, and possibly an organ response to
cholesterol emboli. Microshowers of cholesterol
emboli are thought to occur in about 50% of
percutaneous interventions where a guiding catheter
is passed through the aorta.55 Most of the showers are
clinically silent, but in approximately 1% of high-risk
cases, a full blown cholesterol-embolic syndrome canFig. 2. Therapeutic algorithm for asymptomatic renal artery
transluminal angioplasty; RA, renal artery.
Eur J Vasc Endovasc Surg Vol 29, May 2005develop, manifested by acute renal failure, mesenteric
ischemia and decreased microcirculation to the extre-
mities. The use of distal intra-renal protection devices
may limit this risk. The overall risk of ARF is
approximately 13% in non-diabetics and 20% in
diabetics undergoing renal angiography.56 Fortu-
nately, the majority are mild, and the incidence of
ARF leading to dialysis is rare (0.5–2.0%), but when it
does occur, may be associated with adverse outcome,
including prolonged hospital stay and mortality.Transplant renal artery stenosis
Transplant renal artery stenosis (TRAS) is a well-
known complication of kidney transplantation and an
important cause of graft dysfunction.57 The incidence
ranges from 1 to 23% as documented in various
studies.58,59 It usually occurs at 3–24 months after renal
transplantation, but this is not universal. The moststenosis. RAS, renal artery stenosis; PTA, percutaneous
Renal Artery Stenosis 487common mode of presentation is hypertension, which
may be of recent onset and refractory to treatment.
The accepted initial interventional treatment of
choice at most centers, PTRA, is recommended for
stenosis that are short, linear, and relatively distal from
the anastomosis.60 Restenosis rates have been reported
to be 10–33%.61,62
Surgical revascularisation is recommended for
stenosis that is severe and anastomotic. Surgery carries
a 15–20% risk of graft loss, 12% risk63,64 of restenosis,
and 5% risk of death. Experience with both modalities
is limited and their use is not without complications,
namely, acute stent thrombosis, restenosis and graft
loss.Conclusion
There are clearly significant limitations to the current
understanding of the optimal treatment of RAS with
regard to the respective roles of medication, PTA
and/or stenting. The trials conducted to date have
largely considered control of hypertension as the
primary outcome, and have paid less attention to the
important consequences of renal failure. The trials are
also limited by the difficulties in conclusively estab-
lishing the pathogenesis of renovascular hypertension
and by statistical factors, including their sample sizes.
None of the trials were blinded, and cross-over
between groups was common. Furthermore, the
majority of these trials did not include stenting as an
option versus PTA. Stenting may prove to be more
successful than PTA alone, as suggested by the cohort
studies. However, for the majority of patients with
hypertension or chronic renal dysfunction, the pre-
ferred mode of therapy for RAS remains unknown.
The outcomes of trials underway are enthusiastically
anticipated. Therefore, until the results of these
prospective trials become available, the algorithms of
diagnosis and treatment are best represented in Fig. 2.References
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